About this trial
A multicenter, retrospective study conducted in male and female population infected with HBV or HCV in east China. HCV part, study will enroll 500 HCV antibody positive and HCV RNA positive patients during 2020.7-2023.12 and then observe the characteristics, duration from diagnosis to treatment, treatment rate and sustained virologic response (SVR12) among eligible female and male patients. HBV part, study will enroll 2000 HBsAg positive patients during 2016.7-2019.12 and then observe the clinical characteristics, natural history, duration from diagnosis to treatment, treatment rate and adherence among eligible female and male patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
≥18 years old
serum HBsAg positive for >6 months
Treatment naïve or,
Patients who had been previously treated for HBV but discontinued for at least 1 year before enrollment
Disqualifiers
HBV/HCV Co-infection
HIV
History of hepatic decompensation or hepatocellular carcinoma
Other carcinoma
Trial population
500 HCV Ab+ and HCV RNA + patients during 2020.7-2023.12 and 2000 HBsAg+ patients during 2016.7-2019.12
Trial design
Cohort
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Treatment Rate in male in HBV cohort
The treatment rate in male populations who meet treatment criteria recommended by China CHB guideline
Treatment Rate in female in HBV cohort
The treatment rate in female populations who meet treatment criteria recommended by China CHB guideline
Treatment Rate in male in HCV cohort
The treatment rate in male populations who meet treatment criteria recommended by China CHC guideline
Treatment Rate in female in HCV cohort
The treatment rate in female populations who meet treatment criteria recommended by China CHC guideline
Secondary outcomes
Distribution of Income levels among male in HBV cohort
categorize into 3 levels - low income (less than 50,000 CNY/year), medium income (50,000-300,000 CNY/year), high income (more than 300,000 CNY/year), in male populations infected with HBV
Distribution of Income levels among female in HBV cohort
categorize into 3 levels - low income (less than 50,000 CNY/year), medium income (50,000-300,000 CNY/year), high income (more than 300,000 CNY/year), in female populations infected with HBV
Distribution of medical insurance type in male in HCV cohort
categorize into 4 types - employee medical insurance, resident medical insurance, new rural cooperative medical scheme, self-pay, in male populations infected with HCV
Distribution of medical insurance type in female in HCV cohort
categorize into 4 types - employee medical insurance, resident medical insurance, new rural cooperative medical scheme, self-pay, in male populations infected with HCV
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: